Precision BioSciences, Inc.

Equities

DTIL

US74019P2074

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
9.38 ^USD	-3.50%		-3.70%	-14.34%

Apr. 16	Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration	MT
Apr. 16	Transcript : Precision BioSciences, Inc. - Special Call

Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 27, 2024 at 07:16 am EDT

Precision BioSciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 48.73 million compared to USD 25.1 million a year ago. Net loss was USD 61.32 million compared to USD 111.64 million a year ago.

Basic loss per share from continuing operations was USD 11.07 compared to USD 24.88 a year ago. Basic loss per share was USD 15.96 compared to USD 38.1 a year ago.

Latest news about Precision BioSciences, Inc.

Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration	Apr. 16	MT
Transcript : Precision BioSciences, Inc. - Special Call	Apr. 16
Precision BioSciences, Inc. Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	Apr. 16	CI
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Precision BioSciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27	CI
Earnings Flash (DTIL) PRECISION BIOSCIENCES Posts Q4 Revenue $7M	Mar. 27	MT
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency	Mar. 06	CI
Precision BioSciences Launches $40 Million Public Offering; Shares Slump	Mar. 01	MT
Precision BioSciences, Inc. Announces Non-Exclusive Patent License Agreement with Caribou Biosciences	Feb. 20	CI
Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness	Feb. 14	CI
Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.	Feb. 11	CI
Precision BioSciences Announces 1-for-30 Reverse Stock Split; Shares Fall	Feb. 09	MT
TG Therapeutics Acquires Worldwide License to Precision BioSciences' Allogeneic CD19 CAR T Cell Therapy Program	Jan. 09	MT
TG Therapeutics, Inc. Announces Global License Agreement with Precision BioSciences, Inc. for the Development and Commercialization of Precision?s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases	Jan. 09	CI
Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure	Dec. 13	CI
Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases	Dec. 04	CI
Transcript : Precision BioSciences, Inc. - Special Call	Nov. 13
Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD?s The Liver Meeting 2023	Nov. 13	CI
Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q3 Revenue $13.1M	Nov. 07	MT
Precision BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
US FDA Transfers Cancer Medication Application to Imugene	23-09-28	MT
Sector Update: Health Care Stocks Gain Premarket Wednesday	23-09-27	MT
Precision BioSciences Says it Received Notice of Allowance for US Patent Covering Treatment for Mitochondrial Diseases	23-09-27	MT
Precision BioSciences, Inc.(NasdaqGS:DTIL) dropped from S&P Global BMI Index	23-09-18	CI
Transcript : Precision BioSciences, Inc. - Special Call	23-09-12

Chart Precision BioSciences, Inc.

Duration

Period

More charts

Company Profile

Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform. ARCUS is designed to be precise in its specificity and versatile in its design for gene knock out as well as complex edits with gene insertion and gene repair. ARCUS is also relatively small size, which potentially allows delivery to a range of cells and tissues using viral and non-viral gene delivery methods. Genome editing is a biotechnology process that removes, inserts or repairs a portion of deoxyribonucleic acid (DNA) at a specific location in a cell's genome. There are two primary mechanisms of DNA repair, non-homologous end joining, and homology directed repair. There are several genomes editing technologies, including ARCUS, zinc-finger nucleases, TAL-effector nucleases, CRISPR/Cas9, and base editors.

Sector

More about the company